AUTHORS
Rahul Kumar Thakur, MD, Nikhil Chaudhary2, Xiaoyi Zhang, M.D.3, Sandhya Mishra4, Shaniza Haniff, MD MPH5, Wajeeha Aiman, MD6, Matthew J. Cortese, MD, MPH7, Brian C. Betts, MD8, Shernan Holtan, MD9, James Driscoll II, MD, PhD10, Marco Davila, MD, PhD11, Ehsan Malek, MD12
AFFILIATIONS
1 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
2 South Dakota State University, Brookings, South Dakota, United States
3 NYC Health & Hospital/Jacobi, Albert Einstein College of Medicine, New York, New York, United States
4 University at Buffalo, Buffalo, United States
5 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
6 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
7 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
8 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
9 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
10 University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
11 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
12 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
ABSTRACT
Background:
Chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the treatment of relapsed/refractory multiple myeloma (MM), and ongoing clinical development is expanding CAR-T to various targets, constructs, and treatment settings. However, participation in these trials depends on access to specialized cellular therapy center. Although geographic disparities in CAR-T access have been described whether the distribution of MM CAR-T clinical trials aligns with the underlying geographic burden of MM remains poorly characterized. We evaluated the evolution of MM CAR-T clinical trials across the United States and examined whether population-level geographic accessibility corresponds with state-level MM disease burden.
Methods:
Interventional MM CAR-T clinical trials initiated between 2017 and 2025 were identified from ClinicalTrials.gov. Trial characteristics, including sponsor type, phase, participating institutions, and US trial locations, were extracted. State-level MM burden was estimated using 5-year aggregate incidence data from the CDC United States Cancer Statistics registry and converted to average annual incident cases. Geographic accessibility was estimated using US Census Bureau population-weighted county centroids. Straight-line distance from each county centroid to the nearest MM CAR-T trial site was calculated, and the population-weighted proportion of residents living within 60 and 120 miles of an active trial site was determined for each state. Associations between state-level MM burden and population-weighted geographic accessibility were evaluated using Spearman correlation and ordinary least squares (OLS) linear regression.
Results:
Thirty-four interventional MM CAR-T clinical trials were identified between 2017 and 2025. Trial activity increased substantially, with 27 of 34 trials (79.4%) initiated during 2021–2025 compared with 7 (20.6%) during 2017–2020. Eighteen trials (52.9%) were industry-sponsored and 16 (47.1%) were nonindustrial-sponsored. Overall, 22 trials (64.7%) were phase I/I-II and 12 (35.3%) were phase II/III.
These trials were conducted across 106 unique US trial locations, although geographic expansion remained concentrated within a limited number of states. New York contained the largest number of trial sites (n=51), whereas 19 states had no in-state MM CAR-T trial site. Population-weighted accessibility analysis demonstrated that neighboring trial centers partially mitigated some of these gaps; however, only 68.5% of the US population resided within 60 miles of an active MM CAR-T trial site, increasing to 85.6% within 120 miles. Despite extending the travel threshold, 12 states remained without population access within 60 miles and 6 states remained without access even within 120 miles.
States with higher MM burden generally demonstrated greater population-level geographic accessibility, although this relationship was modest. States with similar MM burden frequently exhibited markedly different levels of patient access. Geographic accessibility was moderately correlated with MM burden (Spearman ρ=0.57 for 60-mile access and ρ=0.50 for 120-mile access; both P<0.001). Linear regression demonstrated that MM burden explained only 21.2% and 16.5% of the variation in accessibility at the 60- and 120-mile thresholds, respectively, indicating that the current geographic distribution of MM CAR-T trial access is only partially aligned with where patients with MM reside.
Conclusions:
Rapid expansion of MM CAR-T clinical trials has not translated into geographically equitable patient access. Population-weighted accessibility demonstrated persistent regional disparities, with several high-burden states remaining substantially underserved despite expansion of the national trial network. Future trial-site selection should incorporate both disease burden and geographic accessibility to improve equitable access to MM CAR-T clinical trials.
DISCLOSURES
Rahul Kumar Thakur, MD: No relevant conflicts of interest to declare.